Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23501241 | 0.84 | CYP4F2 (0.57) | CYP4F2CYP4A11HSP90AB1ALDH1A1NPC1 | |
| SCHEMBL112628 | 0.84 | CYP4F2 (0.51) | CYP4F2CYP4A11HSP90AB1ALDH1A1NPC1 | |
| SCHEMBL23501260 | 0.83 | CA2 (0.50) | ALDH1A1LMNAGAAPARP1TSHR | |
| SCHEMBL23501267 | 0.82 | CYP4A11 (0.54) | CYP4F2CYP4A11HSP90AB1ALDH1A1NPC1 | |
| SCHEMBL13021535 | 0.81 | PARP1 (0.37) | CYP4F2CYP4A11ALDH1A1PARP1HTT | |
| SCHEMBL4113212 | 0.78 | CYP4F2 (0.76) | CYP4F2CYP4A11HSP90AB1ALDH1A1NPC1 | |
| SCHEMBL9889127 | 0.77 | TAAR1 (0.45) | ALDH1A1LMNAPARP1TP53CYP3A4 | |
| SCHEMBL3272099 | 0.77 | RXRA (0.53) | ALDH1A1NPC1RAB9APARP1SMN1; SMN2 | |
| SCHEMBL16639667 | 0.76 | TSHR (0.50) | ALDH1A1LMNASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL9435638 | 0.76 | CYP4F2 (0.50) | CYP4F2CYP4A11HSP90AB1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3845276-B1 | BETA-AMINO ACID DERIVATIVE, KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND USE OF THE SAME | IND TECH RES INST (TW) | 2025-01-29 | — | — | EP | disclosed |
| CN-113121443-B | Beta-amino acid derivatives, kinase inhibitors and pharmaceutical compositions containing them and their use | 财团法人工业技术研究院 | 2024-07-09 | — | — | CN | disclosed |
| CN-112979675-B | Small molecular sulfur-containing heterocyclic compound | 维眸生物科技（上海）有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-11608319-B2 | Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and method for performing an in vivo related application that benefits from the inhibition of a kinase | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2023-03-21 | — | — | US | disclosed |
| US-20220363645-A1 | BETA-AMINO ACID DERIVATIVE, KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND METHOD FOR PERFORMING AN IN VIVO RELATED APPLICATION THAT BENEFITS FROM THE INHIBITION OF A KINASE | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2022-11-17 | — | — | US | disclosed |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2021-11-25 | — | — | US | disclosed |
| CN-111217834-B | Nitroxide derivatives of ROCK kinase inhibitors | 维眸生物科技（上海）有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-113121443-A | Beta-amino acid derivatives, kinase inhibitors and pharmaceutical compositions containing the same and use thereof | 财团法人工业技术研究院 | 2021-07-16 | — | — | CN | disclosed |
| EP-3845276-A1 | SS-AMINO ACID DERIVATIVE, KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND USE OF THE SAME | Industrial Technology Research Institute (TW) | 2021-07-07 | — | — | EP | disclosed |
| US-8394826-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394826-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| EP-2424842-A2 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2424857-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | Aerie Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
| WO-2010127329-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127330-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHAMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010126626-A2 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | CYP4F2 1873/4885CYP4A11 1083/4885HSP90AB1 856/4885 |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | CYP4F2 1873/4885CYP4A11 1083/4885HSP90AB1 856/4885 |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | CYP4F2 2762/4885CYP4A11 1802/4885HSP90AB1 705/4885 |
| US-11608319-B2 | Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and method for performing an in vivo related application that benefits from the inhibition of a kinase | CSNK1A1, CSNK1D, CSNK1G3 | CYP4F2 3024/4885CYP4A11 2718/4885HSP90AB1 1989/4885 |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | CYP4F2 1873/4885CYP4A11 1083/4885HSP90AB1 856/4885 |
| US-20220363645-A1 | BETA-AMINO ACID DERIVATIVE, KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND METHOD FOR PERFORMING AN IN VIVO RELATED APPLICATION THAT BENEFITS FROM THE INHIBITION OF A KINASE | CSNK1A1, CSNK1D, CSNK1G3 | CYP4F2 3024/4885CYP4A11 2718/4885HSP90AB1 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.